Evidence map›Paper›PMID 34079081›Full record

ArticleBritish journal of cancer2021

Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.

Thomas Decaens, Carlo Barone, Eric Assenat, Martin Wermke, Angelica Fasolo, Philippe Merle, Jean-Frédéric Blanc, Véronique Grando, Angelo Iacobellis, Erica Villa and 7 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Thomas DecaensUniversity Grenoble Alpes, Department of Hepato-Gastroenterology and Digestive Oncology, CHU Grenoble Alpes, Institute for Advanced Biosciences INSERM U1209, Grenoble, France. tdecaens@chu-grenoble.fr.ORCID http://orcid.org/0000-0003-0928-0048
Carlo BaroneMedical Oncology, Policlinico Universitario A. Gemelli, Roma, Italy.
Eric AssenatMedical Oncology, CHU Saint Eloi, Montpellier, France.
Martin WermkeNCT/UCC Early Clinical Trial Unit, University Hospital Carl-Gustav-Carus, Dresden, Germany.
Angelica FasoloOncology, IRCCS San Raffaele, Milan, Italy.
Philippe MerleService d'Hépato-Gastro-Entérologie, Hôpital de la Croix Rousse, Lyon, France.
Jean-Frédéric BlancService d'Hépato-Gastroentérologie et d'Oncologie Digestive, Groupe Hospitalier Haut-Lévêque, CHU Bordeaux, Pessac, France.
Véronique GrandoService Hépatologie, Hôpital Jean-Verdier, Bondy, France.
Angelo IacobellisReparto di Gastroenterologia ed Endoscopia Digestiva, Ospedale Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy.
Erica VillaDivision of Gastroenterology Policlinico di Modena, Modena, Italy.
Joerg TrojanGastrointestinal Oncology, Goethe University Hospital, Frankfurt, Germany.
Josef StraubClinical Biomarker & Companion Diagnostics, Merck KGaA, Darmstadt, Germany.
Rolf BrunsBiostatistics, Merck KGaA, Darmstadt, Germany.
Karin BerghoffGlobal Patient Safety Innovation, Merck KGaA, Darmstadt, Germany.
Juergen ScheeleGlobal Clinical Development Oncology, Merck KGaA, Darmstadt, Germany.
Eric RaymondMedical Oncology, Paris-St Joseph Hospital, Paris, France.
Sandrine FaivreMedical Oncology, Saint-Louis Hospital & Paris 7 University, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34079081
PMCPMC8329044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.